Anitha Ramadas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anitha Ramadas has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anis Kausar Ghazali
Biostatistics and Research Methodology Unit, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kelantan, Malaysia
1 shared publication - Bee Kiau Ho
Ministry of Health Malaysia, Putrajaya 62590, Malaysia
1 shared publication Chee Loon Leong
Consultant Infectious Disease Physician, Department of Medicine
1 shared publicationFarida Hanim Islahudin
Faculty of Pharmacy, Universiti Kebangsaan Malaysia
1 shared publicationHwei Lin Teh
Department of Pharmacy, Hospital Kuala Lumpur,50586 Kuala Lumpur, Malaysia
1 shared publication- Hwei Lin Teh
Hosp Kuala Lumpur, Pharm Dept, Kuala Lumpur, Malaysia
1 shared publication
Latest Publications
- Open Access
- 1 June 2022
- Published by Malaysian Pharmacists Society in Malaysian Journal of Pharmacy
- Vol. 8 (1) , 13-18
Impact of an Antibiotic Stewardship Program on the Use of Carbapenem in a Malaysian Tertiary Hospital (ACTION)
Introduction: The Antimicrobial Stewardship (AMS) program had been advocated to promote the rational use of antibiotic prescribing. However, the outcome of AMS in promoting the judicious use of carbapenem, and thus, minimising resistance, has not been widely studied in Malaysia. Objective: To investigate the types of interventions made by the AMS team, their acceptance, and the impact of such interventions on carbapenem consumption as well as the resistance pattern of carbapenem-resistant Enterobacterales (CRE). Method: This was a retrospective study conducted in adult medical wards of the Kuala Lumpur General Hospital (HKL), whereby data was extracted from the AMS forms of patients and subsequently reviewed by the AMS team from January to December 2016. Result and Discussion: The mean (SD) age of 169 patients included in this study was 59.2 (10.6) years. Ertapenem was the most prescribed carbapenem (44.4%), followed by meropenem (34.3%) and imipenem/cilastatin (21.3%). The study demonstrated that only 32% of carbapenem therapy had been empirically initiated, while, 68 cases (40.2%) were classified as unjustified use. Out of these cases, 39 cases (57%) were recommended to be discontinued, 25 cases (37%) were to be de-escalated and 4 cases (6%) were set for changing/escalation. The acceptance rate was reported to be around 73.5% (50 out of 68 cases). After one year of AMS implementation, carbapenem consumption (as shown by the defined daily dose/1000 inpatient bed-days) reduced by 33.7%. Similarly, a notable decrease in CRE cases (33.3%) was observed following a year of AMS initiation. Conclusion: AMS-guided interventions were able to demonstrate a reduction in carbapenem consumption as well as CRE rates in the medical wards.
- 1 June 2022
- Published by Malaysian Pharmacists Society in Malaysian Journal of Pharmacy
- Vol. 8 (1) , 13-18
Open AccessImpact of an Antibiotic Stewardship Program on the Use of Carbapenem in a Malaysian Tertiary Hospital (ACTION)
Introduction: The Antimicrobial Stewardship (AMS) program had been advocated to promote the rational use of antibiotic prescribing. However, the outcome of AMS in promoting the judicious use of carbapenem, and thus, minimising resistance, has not been widely studied in Malaysia. Objective: To investigate the types of interventions made by the AMS team, their acceptance, and the impact of such interventions on carbapenem consumption as well as the resistance pattern of carbapenem-resistant Enterobacterales (CRE). Method: This was a retrospective study conducted in adult medical wards of the Kuala Lumpur General Hospital (HKL), whereby data was extracted from the AMS forms of patients and subsequently reviewed by the AMS team from January to December 2016. Result and Discussion: The mean (SD) age of 169 patients included in this study was 59.2 (10.6) years. Ertapenem was the most prescribed carbapenem (44.4%), followed by meropenem (34.3%) and imipenem/cilastatin (21.3%). The study demonstrated that only 32% of carbapenem therapy had been empirically initiated, while, 68 cases (40.2%) were classified as unjustified use. Out of these cases, 39 cases (57%) were recommended to be discontinued, 25 cases (37%) were to be de-escalated and 4 cases (6%) were set for changing/escalation. The acceptance rate was reported to be around 73.5% (50 out of 68 cases). After one year of AMS implementation, carbapenem consumption (as shown by the defined daily dose/1000 inpatient bed-days) reduced by 33.7%. Similarly, a notable decrease in CRE cases (33.3%) was observed following a year of AMS initiation. Conclusion: AMS-guided interventions were able to demonstrate a reduction in carbapenem consumption as well as CRE rates in the medical wards.
- Open Access
- 27 December 2021
- Published by MDPI AG in Antibiotics
- Vol. 11 (1) , 22
Impact of Extended and Restricted Antibiotic Deescalation on Mortality
Background: More data are needed about the safety of antibiotic de-escalation in specific clinical situations as a strategy to reduce exposure to broad-spectrum antibiotics. This study aims to compare the survival curve of patient de-escalated (early or late) against those not de-escalated on antibiotics, to determine the association of patient related, clinical related, and pressure sore/device related characteristics on all-cause 30-day mortality and determine the impact of early and late antibiotic de-escalation on 30-day all-cause mortality. Methods: This is a retrospective cohort study on patients in medical ward Hospital Kuala Lumpur, admitted between January 2016 and June 2019. A Kaplan–Meier survival curve and Fleming–Harrington test were used to compare the overall survival rates between early, late, and those not de-escalated on antibiotics while multivariable Cox proportional hazards regression was used to determine prognostic factors associated with mortality and the impact of de-escalation on 30-day all-cause mortality. Results: Overall mortality rates were not significantly different when patients were not de-escalated on extended or restricted antibiotics, compared to those de-escalated early or later (p = 0.760). Variables associated with 30-day all-cause mortality were a Sequential Organ Function Assessment (SOFA) score on the day of antimicrobial stewardship (AMS) intervention and Charlson’s comorbidity score (CCS). After controlling for confounders, early and late antibiotics were not associated with an increased risk of mortality. Conclusion: The results of this study reinforce that restricted or extended antibiotic de-escalation in patients does not significantly affect 30-day all-cause mortality compared to continuation with extended and restricted antibiotics.
- 27 December 2021
- Published by MDPI AG in Antibiotics
- Vol. 11 (1) , 22
Open AccessImpact of Extended and Restricted Antibiotic Deescalation on Mortality
Background: More data are needed about the safety of antibiotic de-escalation in specific clinical situations as a strategy to reduce exposure to broad-spectrum antibiotics. This study aims to compare the survival curve of patient de-escalated (early or late) against those not de-escalated on antibiotics, to determine the association of patient related, clinical related, and pressure sore/device related characteristics on all-cause 30-day mortality and determine the impact of early and late antibiotic de-escalation on 30-day all-cause mortality. Methods: This is a retrospective cohort study on patients in medical ward Hospital Kuala Lumpur, admitted between January 2016 and June 2019. A Kaplan–Meier survival curve and Fleming–Harrington test were used to compare the overall survival rates between early, late, and those not de-escalated on antibiotics while multivariable Cox proportional hazards regression was used to determine prognostic factors associated with mortality and the impact of de-escalation on 30-day all-cause mortality. Results: Overall mortality rates were not significantly different when patients were not de-escalated on extended or restricted antibiotics, compared to those de-escalated early or later (p = 0.760). Variables associated with 30-day all-cause mortality were a Sequential Organ Function Assessment (SOFA) score on the day of antimicrobial stewardship (AMS) intervention and Charlson’s comorbidity score (CCS). After controlling for confounders, early and late antibiotics were not associated with an increased risk of mortality. Conclusion: The results of this study reinforce that restricted or extended antibiotic de-escalation in patients does not significantly affect 30-day all-cause mortality compared to continuation with extended and restricted antibiotics.